The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year

Journal of Psychiatric Research

Volumn 43, Issue 13, 2009, Pages 1106-1111

  Schorr, S G ^a,b   Slooff, C J ^b,c   Bruggeman, R ^a,c   Taxis, K ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Mental Health Centre Assen   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antipsychotic agents; Cohort studies; Metabolic syndrome x; Prospective studies; Psychotic disorders; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HYPNOTIC AGENT; LIPID; MOOD STABILIZER; MUSCARINIC RECEPTOR BLOCKING AGENT; OLANZAPINE; RISPERIDONE;

ABDOMINAL OBESITY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE DURATION; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SCHIZOPHRENIA;

EID: 68949208583     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2009.03.002     Document Type: Article

References (29)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
2. Atkins M., Burgess A., Bottomley C., and Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatric Bulletin 21 (1997) 224-226
3. Balkau B., Charles M.A., Drivsholm T., Borch-Johnsen K., Wareham N., Yudkin J.S., et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes and Metabolism 28 (2002) 364-376
4. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., and Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophrenia Research 90 (2007) 162-173
5. Bos M.B., de Vries J.H., Wolffenbuttel B.H., Verhagen H., Hillege J.L., and Feskens E.J. The prevalence of the metabolic syndrome in the Netherlands: increased risk of cardiovascular diseases and diabetes mellitus type 2 in one quarter of persons under 60. Nederlandse Tijdschrift voor Geneeskunde 151 (2007) 2382-2388
6. Brown S., Birtwistle J., Roe L., and Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 29 (1999) 697-701
7. De Hert M.A., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Research 83 (2006) 87-93
8. De Hert M., Schreurs V., Sweers K., Van Eyck D., Hanssens L., Sinko S., et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophrenia Research 101 (2008) 295-303
9. Dekker J.M., Girman C., Rhodes T., Nijpels G., Stehouwer C.D., Bouter L.M., et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 112 (2005) 666-673
10. Fernandez-Egea E., Miller B., Bernardo M., Donner T., and Kirkpatrick B. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophrenia Research 98 (2008) 302-306
11. Graham K.A., Cho H., Brownley K.A., and Harp J.B. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophrenia Research 101 (2008) 287-294
12. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., and Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
13. Hanley A.J., Karter A.J., Williams K., Festa A., D'Agostino Jr. R.B., Wagenknecht L.E., et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 112 (2005) 3713-3721
14. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. The Journal of the American Medical Association (JAMA) 288 (2002) 2709-2716
15. Lamberti J.S., Olson D., Crilly J.F., Olivares T., Williams G.C., Tu X., et al. Prevalence of the metabolic syndrome among patients receiving clozapine. American Journal of Psychiatry 163 (2006) 1273-1276
16. L'italien G.J., Casey D.E., Kan H.J., Carson W.H., and Marcus R.N. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. The Journal of Clinical Psychiatry 68 (2007) 1510-1516
17. McCreadie R.G. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. British Journal of Psychiatry 183 (2003) 534-539
18. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80 (2005) 19-32
19. Meyer J.M., Davis V.G., Goff D.C., McEvoy J.P., Nasrallah H.A., Davis S.M., et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophrenia Research 101 (2008) 273-286
20. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. British Journal of Psychiatry Supplement 47 (2004) S102-S105
21. Poirier M.F., Canceil O., Bayle F., Millet B., Bourdel M.C., Moatti C., et al. Prevalence of smoking in psychiatric patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26 (2002) 529-537
22. Saddichha S., Manjunatha N., Ameen S., and Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophrenia Research 101 (2008) 266-272
23. Schorr S.G., Slooff C.J., Postema R., Schilthuis M., Bruggeman R., and Taxis K. A 12-month follow-up study of treating overweight patients with aripiprazole. Acta Psychiatrica Scandinavica 118 (2008) 246-250
24. Schorr SG, Slooff CJ, Bruggeman R, Taxis K. Prevalence of metabolic syndrome in schizophrenic patients in the Netherlands. Journal of Clinical Psychopharmacology 2009, accepted for publication.
25. Spelman L.M., Walsh P.I., Sharifi N., Collins P., and Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetic Medicine 24 (2007) 481-485
26. Srisurapanont M., Likhitsathian S., Boonyanaruthee V., Charnsilp C., and Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC.Psychiatry 7 (2007) 14
27. Taylor D., Paton C., and Kerwin R. The Maudsley 2005-2006 prescribing guidelines (2005), Taylor and Francis, London and New York
28. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64 (2003) 663-667
29. Zhu S., St-Onge M.P., Heshka S., and Heymsfield S.B. Lifestyle behaviors associated with lower risk of having the metabolic syndrome. Metabolism 53 (2004) 1503-1511